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Purpose. Following the publication of a prospective randomized trial (EVAR2) that questioned the benefit of endovascular
repair of abdominal aortic aneurysms (AAA) for high-surgical-risk patients, we evaluated our own initial and long-term
results with endovascular AAA repair for this patient population.
Material and methods. Between January 2000 and December 2005, 115 patients with an AAA managed by an aortic
endograft were entered in a registry. Data concerning diagnosis, operative risk, treatment, and follow-up were analyzed
on an intention-to-treat basis for all patients considered to be poor candidates for surgery. Patients with a ruptured
AAA and those who were good surgical candidates were excluded from analysis. The main goal was evaluation of the
operative mortality and the long-term survival of these patients. Secondary goals were determination of the frequency
of secondary operations, the outcome of the aneurysm sac, and primary and secondary patency rates after aortic endograft
placement.
Results. A total of 92 high-surgical-risk patients treated by an endograft were entered in this study. Sixty-seven patients
(73%) were classed ASA III and 18 (20%) were ASA IV (20%). Mean aneurysm diameter was 58 mm 9 mm. The
technical success rate was 99%. Operative mortality was 4.3% (4 cases). Four patients required re-intervention during
the mean follow-up of 18 months. The survival rate at 3 yr was 85%. One type I endoleak (1%) and 9 type II endoleaks
(9.7%) occurred during the follow-up period. Primary and secondary patency rates at 3 yr were respectively 96% and 100%.
Conclusion. Our initial and long-term results with endograft repair of AAA in high-surgical-risk patients were satisfac-
tory. These results appear to justify endovascular repair for this patient population.
Keywords: Aneurysm; Abdominal aorta; Endograft; Endovascular; High-surgical-risk patient.Two randomized prospective studies1,2 concerning
patients who are good surgical risk candidates have
reported a significant decrease in immediatemorbidity
and mortality after endovascular repair of abdominal
aortic aneurysms (AAA) compared to conventional
open surgery. Nevertheless, the uncertainties concern-
ing the long-term outcome of aortic endografts have
prompted several scientific societies to recommend
that this approach be reserved for so-called high surgi-
cal risk patients. However, recent data on endovascular
AAA repair includes both a high frequency of second-
ary procedures3e5 and elevated rates of immediate and
late morbidity and mortality in high-surgical-risk pa-
tients.5 This study describes our initial and long-term
* Study presented at the 21st Annual Congress of the French
Society for Vascular Surgery, Arcachon, France, June 19th, 2006.
*Corresponding author. Prof. R. Hassen-Khodja, Department of
Vascular Surgery, Hoˆpital Saint Roch, 5 rue Pierre De´voluy - BP
1319, 06006 Nice Cedex 1, France.
E-mail address: hassen-khodja.r@chu-nice.fr1078–5884/000145+ 07 $32.00/0  2007 Elsevier Ltd. All rights reseresults with endovascular repair of AAA in high-
surgical-risk patients.
Material and Methods
Between January 2000 and December 2005, a total of
115 patients with an infrarenal AAA managed at our
center by aortic endograft placement were included
in a registry. All patients underwent preoperative eval-
uation consisting of aortographywith a graduated pig-
tail catheter and contrast-enhanced CT with 3e5 mm
slices. Data concerning diagnosis, operative risk, treat-
ment, and follow-up were collected prospectively in
a registry. Ninety-two of these 115 patients (80%)
with a non-ruptured AAAwere considered poor can-
didates for surgery and were included in this study.
Patients who underwent emergency repair of a rup-
tured AAA (10 cases) and good-surgical-risk patients
(13 cases) were excluded from analysis. These 92 high-
surgical-risk patients were selected for endovascularrved.
146 E. Jean-Baptiste et al.repair after discussion between the surgeons and the
anaesthetists of our Department. The decision to in-
clude these patients in an endovascular repair protocol
was based on the existence of favourable anatomic con-
ditions for aortic endograft placement and the pres-
ence of one or more of the following criteria used by
the AFSSAPS (Agence Franc¸aise de Se´curite´ Sanitaire
des Produits de Sante´) to define high-surgical-risk
candidates:
1. age 80 yr or over
2. coronary artery disease evidenced by a history of
myocardial infarction or angina with a positive
function test and non-revascularizable coronary
artery lesions
3. symptomatic heart failure
4. inoperable tight aortic narrowing
5. left ventricular ejection fraction< 40%of predicted
6. COPD evidenced by FEV1<1.2 l/sec, vital capacity
< 50% of the predicted value as a function of age,
sex and weight, arterial PaCO2> 45 mm Hg or
PaO2< 60 mmHg, or home oxygen therapy
7. renal failure corresponding to serum creatinine
greater than or equal to 200 micromol/l prior to
contrast medium injection
8. hostile abdomen owing to the presence of ascites
or other signs of portal hypertension.
Graft placement was performed in the operating
theatre under general or local-regional anaesthesia us-
ing a limited femoral surgical approach or, in certain
cases, a percutaneous approach (Prostar system,
Abbott). A bifurcated endograft was used except
when the diameter of the distal aortic neck was
smaller than 24 mm or when there were calcifications,
tortuous iliac arteries or iliac occlusion. In the later
cases, a uniiliac endograft was preferred and com-
bined with a crossover bypass and occlusion of the
contralateral iliac artery. Postoperative follow-up con-
sisted of clinical examination and follow-up CT 1 mo.,
6 mo., 12 mo. and 18 mo. after intervention, then an-
nually if the 18 mo. results were satisfactory. Patients
with renal failure were followed up on an alternating
basis by Doppler ultrasound and CT. All radiological
images were reinterpreted conjointly with a vascular
radiologist. The data base of clinical and imaging
information thus obtained was reviewed, then com-
pleted by analysis of the files of all of the patients in-
cluded in this series. The main goal of this study was
to evaluate the operative mortality and the long-term
survival of high surgical risk patients with an infrare-
nal AAA treated by an aortic endograft. The secondary
goals were to determine the primary and secondary
patency rates, the frequency of secondary procedures,Eur J Vasc Endovasc Surg Vol 34, August 2007and the outcome of the aneurysm sac after aortic en-
dograft placement. Operative mortality was defined
as any death occurring the first 30 days after endograft
placement, regardless of the cause. Secondary inter-
ventions included any complementary surgical or en-
dovascular procedure performed immediately after
or at a distance from endograft placement in order to
maintain a satisfactory clinical result or to treat a spe-
cific complication linked to the endograft or the aneu-
rysm. The outcome of the aneurysm sac was evaluated
by postoperative measurement of aneurysm diameter
during follow-up.
Statistical analysis on an intention-to-treat basis was
performed using STAT VIEW software (SAS Institute,
Inc. 1992e1998; version 5.0). Measured values were
expressed as the mean standard deviation, or as
ranges. TheKaplan-Meiermethodwasused to calculate
the survival and patency rates. A t-test was used to
compare the mean duration of hospitalization between
the subgroup of patients treated with a bifurcated
endograft and those treated by a uniiliac endograft
combined with a femoro-femoral crossover bypass. A
P value< 0.05 was considered statistically significant.
Results
A total of 92 patients (82 men, 10 women) were consid-
ered high-surgical-risk candidates and were included
in our study. Mean age was 77 yr (range 53e100). The
major comorbidities of the patients in our series are
listed in Table 1. Of the 66 patients with recognized
severe cardiac disease, 29 had coronary artery disease,
9 had a left ventricular ejection fraction less than 40%,
and 20 patients had multiple associated cardiac events
(heart failure, arrhythmia, coronary artery disease).
Seven patients were classed ASA II (8%), 67 were
ASA III (73%), and 18 were ASA IV (20%). Multiple
severe co-morbidities were present in all ASA IV pa-
tients. Those classified ASA III had at least one major
life threatening condition (cardiac disease, renal failure
or significant chronic respiratory disease) and other
minor problems like hypertension, tobacco abuse, or
diabetes. Six of the 7 ASA II patients were elderly
Table 1. Risk factor data for the patients in our series (N[ 92)
Factor N %
Diabetes 11 11.9%
Arterial hypertension 58 63.0%
Smoking 47 51.1%
COPD 38 41.3%
Cardiopathy 66 71.7%
Creatinemia> 200 micromol/l 9 9.8%
COPD: chronic obstructive pulmonary disease.
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a hostile abdomen owing to obesity, multiple previous
laparotomies, and a colostomy. Table 2 displays how
many patients were unfit for open repair according to
each single AFSSAPS criteria. For comparative pur-
poses we report howmanywould be at high risk accor-
ding to each single EVAR2 criteria6 (Table 2). Mean
body mass index in this population was 25 (range
15e33). Mean aneurysm diameter was 58 mm 9 mm.
The mean length of the proximal aneurysm neck was
18 mm (range 15e30 mm); the mean neck diameter
was 23 mm 5 mm. Fourteen patients had highly tor-
tuous or severely calcified iliac arteries. The technical
success rate was 99% (91/92 cases). A bifurcated endo-
graft was used in 55 cases (14 of them were placed
totally by a bilateral percutaneous approach).
The other 36 patients were managed with an aortic
uniiliac endograft combined with a crossover bypass.
The sole technical failure concerned one of the 14 pa-
tients with severely tortuous iliac arteries and calcifica-
tion. This patient had already had a crossover bypass
for an occlusive left iliac lesion and it was impossible
to insert the endograft. Immediate conversion to
surgery was successful despite this patient’s COPD.
In four other patients, a complementary surgical or
endovascular procedure was required to enable endo-
graft placement. Two of these patients underwent per-
cutaneous transluminal iliac angioplasty to facilitate
advancement of the endograft delivery system. An-
other patient required a hepato-renal bypass following
accidental injury of the right renal artery during en-
dograft deployment. In the last patient, a bifurcated
endograft was converted to a uniiliac endograft com-
bined with a crossover bypass following per-operative
endograft limb occlusion. Eight patients underwentprior unilateral hypogastric embolization because
the aneurysm extended to the internal iliac arteries.
The endografts used included 6 Excluder (WL Gore),
5Aneurix (Medtronic), 14 Talent (Medtronic), and 66
Zenith (Cook).
The mean duration of hospitalization was 9 days
(range 1e32). However, the hospital stay was longer
in the patients managed with an aortic uniiliac endo-
graft plus a femoro-femoral crossover bypass than in
those who received a bifurcated endograft: 11 days
vs 7 days of hospitalization respectively (P¼ 0.0007).
The mean hospital stay of patients treated by a percu-
taneous approach (14 patients) was 5 days. Mortality
at Day 30 was 4.3% (4 patients), corresponding to
1 myocardial infarction, 1 multi-organ failure, 1 colo-
nic ischemia associated with postoperative paraplegia
in a patient who already had a thoracic endograft,
and 1 iliac rupture (small, tortuous and calcified iliac
artery). The four patients who died before the 30th
postoperative day were all males over 80 yr of age
classed ASA IV who had multiple cardiac problems
and COPD. The procedure for these 4 patients were
performed under general anaesthesia.
Mean follow-up was 18 mo. Five late deaths
occurred during this period: 1 heart failure, 1 rupture
of a type I endoleak, 1 deterioration of general status,
1 mesenteric infarction, and 1 case of aspiration pneu-
monia. Actuarial survival at 3 yr was 85% (Fig. 1). Pri-
mary and secondary patency rates at 3 yr were 96%
and 100% respectively (Fig. 2). Three patients devel-
oped buttock claudication that completely resolved
in all cases between 6 and 18 mo. The contralateral
internal iliac artery remained patent in these 3 patients
who had all undergone hypogastric artery emboliza-
tion prior to endograft placement. Four patientsTable 2. Repartition of our patients who would be unfit for open repair according to each AFSSAPS and each EVAR2 criteria (N[ 92)
Function AFSSAPS Criteria N1* EVAR2 Criteria
6 N2
y
Age >80 yrs 38 No 0
Local factors Hostile abdomen 1 No 0
Cardiac CADz 29 ?? (local decisionx) ?
Heart failure** 24 Heart failureyy 24
Inoperable tight aortic stenosis 2 Severe valve disease 2
Renal Serum creatinine> 200mcmoles/l 9 Serum creatinine> 200mcmoles/l 9
Respiratory FEV1<1.2 l/sec FEV1<1.0 l/s
Vital capacity< 50% e
PaCO2> 45 mmHg 38 PaCO2> 6.5 KPa 38
Pa O2< 60 mmHg Pa O2< 8.0 KPa
Home oxygen therapy Short of breath after a flight of stairs
* N1: Number of our patients deemed unfit for open conventional repair according to each AFSSAPS Criteria.y N2: Number of our patients who could be deemed unfit for open conventional repair according to each EVAR2 criteria.
6
z CAD (coronary artery disease) as evidenced by: prior myocardial infarction, or angor with positive function test and non-revascularizable
coronaropathy.
x decision about patient fitness and enrolment into EVAR1 or EVAR2 were dedicated to local surgeon, anaesthetist and radiologist.
** Heart failure: patent manifestations or ejection fraction <40%.
yy Uncontrolled congestive heart failure.Eur J Vasc Endovasc Surg Vol 34, August 2007
148 E. Jean-Baptiste et al.(4.3%) required repeat surgery during follow-up: 3
repeat endovascular repairs and one surgical repair.
The reasons for these repeat procedures are listed in
Table 3. During follow-up, one Type I endoleak (1%)
resulted in a fatal rupture. There were 9 type II endo-
leaks (9.7%): 3 healed spontaneously, 5 persisted with
a stable or regressive aneurysm diameter, and 1 endo-
leak associated with an increase in the size of the an-
eurysm sac was successfully embolized (Table 3).
The aneurysm sac decreased in size by 2 to 30 mm
in 33 patients in this series (36%). In the remaining
patients, the aneurysm sac remained stable during
the entire follow-up period (Fig. 3).
Discussion
Operative mortality in our series of high-surgical-risk
patients who underwent endovascular AAA repair
was 4.3%. The frequency of secondary procedures
during the mean follow-up period of 18 mo. was
4.3%. Survival at 3 yr was 85%, with a significant
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Fig. 1. Kaplan-Meier survival curve.
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Fig. 2. Kaplan-Meier actuarial curve of primary patency.Eur J Vasc Endovasc Surg Vol 34, August 2007reduction in the size of the aneurysm sac in over
one third of cases. Only one of the 5 deaths that
occurred during long term follow-up was related to
the aneurysm and was due to a specific complication
of endografts (type I endoleak). Long-term morbidity
was dominated by the development of type II endo-
leaks (9.7% of cases) and thrombosis or stenosis of
the endograft limb (2.1% of cases). Type II endoleaks
all had a benign course and usually required only
surveillance.
The limitations of our study are those of a retrospec-
tive analysis of data collected in a registry without
prior definition of a control population. Nevertheless,
no patient in this series was lost to follow-up and their
clinical characteristics are comparable to those of most
other studies published on the subject.
Previous studies suggest that endovascular AAA
repair may be a valuable alternative to open repair
for patients with severe comorbidities.7e12 Published
operative mortality rates vary between 0 and 5.3%
for high surgical risk patients. The EVAR25 random-
ized prospective study comparing surveillance and
endovascular repair of AAA in patients for whom
open repair was contraindicated nevertheless reported
a mortality rate on Day 30 of 9% in the endovascular
group. This is more than twice the mortality in our
series. Likewise, long-term survival in EVAR25 (34% at
4 yr) was markedly lower than the long-term survival
of 85% at 3 yr in our study. One might argue that better
results were achieved in our study because of more
lenient inclusion criteria, especially 8% of our patients
were ASA class II patients. However, most of our pa-
tients would have probably qualified as EVAR2 pa-
tients (Table 2). Since the design of both EVAR1 and
EVAR2 trials, it has become clear that there are difficul-
ties in using strict ASA classification for defining risk
among vascular surgery patients.6 For both trials, deci-
sions about patient fitness were made by local sur-
geons, anaesthetists and radiologists.6 ASA 2 patients
are frequently not high risk for open AAA repair, but
in our study the ASA 2 patients (7 cases) were octoge-
narians (6 cases) or had a hostile abdomen (1 case).
Nevertheless, advanced age as a risk factor for aortic
cross-clamping surgery has remained a controversial
issue.13 Haug et al., in a recently published study,
reported an operative mortality rate of 11% for octoge-
narians who underwent conventional AAA repair.14
In a post-hoc analysis of the low risk DREAM trial
population, Baas et al. have found a 2.2 fold increased
risk of death for patients older than 70 years who un-
derwent open aortic repair as compared to patients
younger than 70 years (6.3% vs. 3.2% respectively).15
A possible explanation is that elderly patients, because
of limited daily activity, could have unnoticed cardiac
149Endovascular Repair of AAA in High-Risk-Surgical PatientsTable 3. Secondary procedures
Event Moment of diagnosis Treatment Moment of treatment Result
Type II endoleak 6 mo. Ilio-lumbar embolization 36 mo. Good Follow-up 3 mo.
Type I endoleak (rupture) 2 mo. Surgical conversion 2 mo. Death
Endograft limb thrombosis Day 6 Thrombectomy Day 6 Blue toe syndrome
Endograft stenosis 2 mo. Percutaneous transluminal
angioplasty
2 mo. Good Follow-up 9 mo.Eur J Vasc Endovasc Surg Vol 34, August 2007or respiratory morbidities prone to decompensate by
a surgical insult. Conversely, octogenarians with
AAA should be considered as high risk patients and
be offered the less invasive surgical approach even
without previous cardiac and respiratory problems.
Moreover, other studies8e11 including greater num-
bers of patients (Table 4) corroborate our favourable
results obtained with EVAR in patients unfit for
conventional repair. In the EUROSTAR11 register, the
survival rate at 3 yr was 68% for the group of high-
risk patients who were refused surgery. Sicard et al.8
reported amean survival rate of 56%at 4 yr.Differences
in outcome noted in these registries (Table 4), though
minor, might reflect the lack of universal, homogenous,
and easy-applicable guidelines for defining high risk
populations. With the exception of those patients with
a limited life expectancy for whom the risk of death at
1 yr due to co-morbidities greatly exceeds the risk of
aneurysm rupture, we and most authors8e12 advocate
endovascular repair of AAA for high-surgical-risk
patients, in contrast to the EVAR2.5 Factors including
the therapeutic approach, anatomic features, and statis-
tical bias may explain some of the discrepancies
observed as compared to EVAR2. For example,medical
treatment, a factor that has been proven to influence
patient survival,16,17 was not optimal in nearly half of
the patients in the EVAR25 study.Aside from aneurysm
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Fig. 3. Evolution of aneurysm diameter after aortic endo-
graft placement.diameter, EVAR25 did not report any anatomic charac-
teristics. Mean diameter in EVAR2 was 6.7 cm versus
5.8 cm in our study. However, several literature
studies18e23 suggest that anatomic conditions worsen
as the aneurysm enlarges. Large aneurysm diameter,
like a short, calcified and/or highly angulated neck,
are predictive factors of aortic endograft complications,
both immediately and at long term.22,24e28 Strict respect
of anatomic feasibility conditions for aortic endografts
and a smaller mean aneurysm diameter in our series
compared to EVAR2 may explain our good results.
Clinical and statistical factorsmight also explain the re-
sults in EVAR2.5 Nine of the 20 deaths recorded in the
EVAR2 endovascular group (i.e. 45% of the mortality
in the group)were due to aneurysm rupture in patients
who were waiting for an endograft. The mean interval
between randomization and treatment (mean 57 days,
maximum 767 days) was indeed very long for patients
whose AAA measured a mean diameter of 6.7 cm.
Furthermore, 47 patients of the EVAR25 surveillance
group (27%) were operated on in violation of the study
protocol, although curiously the mortality rate was
only 2.1%, which is similar to our results for this type
of patient.
Another major problem linked to endovascular
AAA repair is the frequency of secondary procedures
required to maintain the immediate results and the re-
sultant increase in the cost of patient management.
Endoleaks are the main cause of repeat intervention
after placement of an aortic endograft.29 In certain se-
ries, 27e35% of the patients treated with an aortic endo-
graft required a secondary procedure at some point
during the first seven years of follow-up.3,4 In the
EVAR2 study, 43% of the endovascular group patients
had at least one postoperative complication and 26%
of the patients required a secondary procedure after
Table 4. Literature review
Study N Mean
age
(yr)
Mean
aneurysm
diameter
(mm)
Deaths at
30 days
Survival
EUROSTAR11 550 72.6 58.3 4.8e5.3% 68% (at 3 yr)
SVS8 565 76.6 64 2.9% 56% (at 4 yr)
EVAR25 166 76.8 64 9% 34% (at 4 yr)
This series 92 77 58 4.3% 85% (at 3 yr)
150 E. Jean-Baptiste et al.4 yr of follow-up.5 These repeat procedures account
for a good percentage of the financial costs linked to
this group.5 However, several other studies have re-
ported surgical or endovascular reintervention rates
varying from 2 to 13%.18,30,31 These figures agree
with the 4.3% reintervention rate in our series. Im-
provement of the endografts on the market may ex-
plain the more favourable results in the most recent
series.28 However, the disparities in reintervention
rates might be due to differences in the diagnostic atti-
tude as well as to differences in therapeutic choices.
Indeed, up to 19% of all type I endoleaks and 49% of
all type II endoleaks have been reported following
systematic arteriography after 1 year of survival.32
The rate of CT-detected endoleaks varies from 4% to
20%, depending on the series.9,30,31 Henao and coll.33
emphasized the role of contrast-enhanced Doppler
ultrasound for the diagnosis of endoleaks. In EVAR2,
the authors reported 5.6% type I endoleaks and 9.5%
type II endoleaks. While type I endoleaks justify an
aggressive approach because they can result in rup-
ture in up to 21% of cases in less than 30 days,26 type
II endoleaks with an aneurysm sac that remains stable
or regresses in size can be treated conservatively.34,35
Endograft limb thrombosis and stenosis are less
common complications of endovascular AAA repair.
In our series, as in EVAR2 and the series of Allaqa-
band and coll.,10 2e4% of patients developed this
type complication that always prompted a repeat sur-
gical or endovascular procedure. According to a recent
study, placement of an additional bare metal stent in
the endograft limb during the initial procedure might
improve long-term patency by reducing the risk of
thrombosis.36
Conclusion
Our initial and long-term results with endografts for
the treatment of AAA in high-surgical-risk patients
were satisfactory as the operative mortality was
4.3%, survival at 3 yr was 85%, and the secondary
procedure rate was only 4.3%. In our opinion, these
results justify endovascular repair for this group of
patients. The most important factor for improvement
of the short and long-term results of aortic endografts
is respect of anatomic feasibility conditions.
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